BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $89

BTIG analyst Kambiz Yazdi has maintained a Buy rating on Rapport Therapeutics (NASDAQ: RAPP) and raised the price target from $75 to $89. This adjustment reflects increased confidence in the company's performance.